Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Quality of life improvements in dialysis patients receiving darbepoetin alfa.

Fukuhara S, Akizawa T, Morita S, Koshikawa S; KRN321 A08 Study Group.

Ther Apher Dial. 2008 Feb;12(1):72-7. doi: 10.1111/j.1744-9987.2007.00544.x.

PMID:
18257816
2.

[Multicenter study of darbepoetin alfa in the treatment of anemia secondary to chronic renal insufficiency on dialysis].

Martínez Castelao A, Reyes A, Valdés F, Otero A, López de Novales E, Pallardó L, Tabernero JM, Hernández Jaras J, Lladós F.

Nefrologia. 2003;23(2):114-24. Spanish.

3.

Association of anemia correction with health related quality of life in patients not on dialysis.

Alexander M, Kewalramani R, Agodoa I, Globe D.

Curr Med Res Opin. 2007 Dec;23(12):2997-3008.

PMID:
17958944
4.

2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.

Tsubakihara Y, Nishi S, Akiba T, Hirakata H, Iseki K, Kubota M, Kuriyama S, Komatsu Y, Suzuki M, Nakai S, Hattori M, Babazono T, Hiramatsu M, Yamamoto H, Bessho M, Akizawa T.

Ther Apher Dial. 2010 Jun;14(3):240-75. doi: 10.1111/j.1744-9987.2010.00836.x.

PMID:
20609178
6.

Darbepoetin alfa once every 2 weeks for treatment of anemia in dialysis patients: a combined analysis of eight multicenter trials.

Mann J, Kessler M, Villa G, Martinez-Castelao A, Feldt-Rasmussen B, Cruz J, Hörl WH, Mattin C, Praml C, Wilkie M.

Clin Nephrol. 2007 Mar;67(3):140-8.

PMID:
17390738
7.

The association of darbepoetin alfa with hemoglobin and health-related quality of life in patients with chronic kidney disease not receiving dialysis.

Abu-Alfa AK, Sloan L, Charytan C, Sekkarie M, Scarlata D, Globe D, Audhya P.

Curr Med Res Opin. 2008 Apr;24(4):1091-100. doi: 10.1185/030079908X280653 . Epub 2008 Mar 6.

PMID:
18328118
8.

Positive outcomes of high hemoglobin target in patients with chronic kidney disease not on dialysis: a randomized controlled study.

Akizawa T, Gejyo F, Nishi S, Iino Y, Watanabe Y, Suzuki M, Saito A, Akiba T, Hirakata H, Fukuhara S, Morita S, Hiroe M, Hada Y, Suzuki M, Akaishi M, Iwasaki M, Tsubakihara Y; KRN321 STUDY Group.

Ther Apher Dial. 2011 Oct;15(5):431-40. doi: 10.1111/j.1744-9987.2011.00931.x. Epub 2011 May 25.

PMID:
21974695
9.

Relationship between hemoglobin level and quality of life in anemic patients with chronic kidney disease receiving epoetin alfa.

Lefebvre P, Vekeman F, Sarokhan B, Enny C, Provenzano R, Cremieux PY.

Curr Med Res Opin. 2006 Oct;22(10):1929-37.

PMID:
17022852
10.

Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm.

Skali H, Lin J, Pfeffer MA, Chen CY, Cooper ME, McMurray JJ, Nissenson AR, Remuzzi G, Rossert J, Parfrey PS, Scott-Douglas NW, Singh AK, Toto R, Uno H, Ivanovich P.

Am J Kidney Dis. 2013 Feb;61(2):238-46. doi: 10.1053/j.ajkd.2012.08.043. Epub 2012 Nov 16.

PMID:
23159232
11.

[Treatment of renal anemia with darbepoetin alfa: results of an Austrian multicenter study].

Hörl WH, Holzer H, Mayer GJ; Osterreichische Aranesp Studiengruppe.

Wien Klin Wochenschr. 2002 Dec 30;114(23-24):967-71. German.

PMID:
12635463
12.

A randomised single-blind study to improve health-related quality of life by treating anaemia of chronic kidney disease with Aranesp® (darbepoetin alfa) in older people: STIMULATE.

Roger SD, Jassal SV, Woodward MC, Soroka S, McMahon LP.

Int Urol Nephrol. 2014 Feb;46(2):469-75. doi: 10.1007/s11255-013-0512-1. Epub 2013 Aug 28.

PMID:
23982766
13.

A prospective cohort study on the impact of darbepoetin alfa on quality of life in daily practice following anemia treatment guideline revisions.

Steinmetz T, Kindler M, Lange O, Vehling-Kaiser U, Kuhn A, Hellebrand E.

Curr Med Res Opin. 2014 Sep;30(9):1813-20. doi: 10.1185/03007995.2014.924914. Epub 2014 Jun 5.

PMID:
24849527
14.

Change in darbepoetin alfa administration schedule affects erythropoiesis-stimulating agent resistance in patients with chronic kidney disease receiving hemodialysis.

Molina M, Navarro MJ, de Gracia C, Alvarez G, de Alarcon R, Garcia MA.

Ren Fail. 2008;30(8):778-83. doi: 10.1080/08860220802248977.

PMID:
18791951
15.

Darbepoetin alfa effectively maintains haemoglobin concentrations at extended dose intervals relative to intravenous or subcutaneous recombinant human erythropoietin in dialysis patients.

Brunkhorst R, Bommer J, Braun J, Haag-Weber M, Gill C, Wagner J, Wagener T; German Aranesp Study Group.

Nephrol Dial Transplant. 2004 May;19(5):1224-30. Epub 2004 Feb 19.

PMID:
14993489
16.
17.
18.

Antianemic effect of once weekly regimen of epoetin alfa 40,000 units in anemic cancer patients receiving chemotherapy.

Voravud N, Sriuranpong V, Suwanrusme H.

J Med Assoc Thai. 2007 Jun;90(6):1082-8.

PMID:
17624200
19.

[Darbepoetin-alfa treatment of anemia secondary to chronic renal failure in dialysis patients: Results of a French multicenter study].

Kessler M, Hannedouche T, Fitte H, Cayotte JL, Urena P, Réglier JC; Groupe de l'étude NESP 20000117.

Nephrol Ther. 2006 Sep;2(4):191-9. Epub 2006 Aug 17. French.

PMID:
16966064
20.

Supplemental Content

Support Center